AbbVie (NYSE:ABBV) Given Outperform Rating at Royal Bank Of Canada

AbbVie (NYSE:ABBV)‘s stock had its “outperform” rating reissued by Royal Bank Of Canada in a report issued on Tuesday, Benzinga reports. They currently have a $280.00 price objective on the stock. Royal Bank Of Canada’s target price points to a potential upside of 1.31% from the company’s previous close.

A number of other research firms have also issued reports on ABBV. Barclays boosted their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Piper Sandler upped their price objective on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Leerink Partners boosted their target price on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Finally, HSBC boosted their price target on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $277.18.

AbbVie Stock Down 1.7%

Shares of AbbVie stock traded down $4.73 during mid-day trading on Tuesday, hitting $276.39. The stock had a trading volume of 1,965,100 shares, compared to its average volume of 6,391,498. The firm has a market cap of $488.32 billion, a P/E ratio of 78.09, a price-to-earnings-growth ratio of 1.26 and a beta of 0.24. The firm has a 50-day moving average of $259.79 and a two-hundred day moving average of $237.39. AbbVie has a 12-month low of $190.75 and a 12-month high of $283.43.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the firm earned $2.97 earnings per share. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts expect that AbbVie will post 13.94 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LP acquired a new position in AbbVie during the 2nd quarter worth $559,736,000. Legal & General Group Plc acquired a new position in AbbVie during the second quarter valued at approximately $2,905,952,000. Jupiter Topco LLC acquired a new position in AbbVie in the 2nd quarter worth $1,560,354,000. Diamant Asset Management Inc. raised its position in AbbVie by 21,649.0% in the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after buying an additional 3,654,351 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in AbbVie during the second quarter worth $817,473,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Fresh clinical and regulatory developments are strengthening AbbVie’s growth narrative. Phase 3 data for SKYRIZI and RINVOQ in Crohn’s disease, along with FDA Breakthrough Therapy Designations for temab-A in colorectal and lung cancer, could expand the company’s long-term commercial opportunities. Early obesity data also add potential upside to the pipeline. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Positive Sentiment: Long-term data presented at ACG 2026 continue to support the durability and growth prospects of SKYRIZI and RINVOQ. Analysts expect the two therapies to offset part of Humira’s revenue erosion and drive third-quarter top-line growth. AbbVie Highlights Long-Term SKYRIZI and RINVOQ Data
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $280 price target, indicating continued confidence in AbbVie’s earnings outlook despite limited near-term upside at current levels.
• Neutral Sentiment: Recent coverage highlights AbbVie as an attractive income stock after market weakness pushed its dividend yield higher. That may support defensive and income-oriented demand, though the yield increase also reflects recent selling pressure. High-Yield Dividend Stocks
• Negative Sentiment: At a lofty valuation following a substantial rally, investors may be taking profits while assessing whether SKYRIZI and RINVOQ can fully replace Humira sales. Rising competition in immunology and the stock’s limited analyst-implied upside are additional near-term headwinds. Will SKYRIZI and RINVOQ Drive AbbVie’s Top-Line Growth?

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.